FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017776654> ?p ?o ?g. }

• W2017776654 endingPage "799" @default.
• W2017776654 startingPage "799" @default.
• W2017776654 abstract "Additive effects of cilnidipine, an L-/N-type calcium channel blocker, and an angiotensin II receptor blocker on reducing cardiorenal damage in Otsuka Long-Evans Tokushima Fatty rats with type 2 diabetes mellitus Yutaka Mori,1,2 Shizuka Aritomi,3 Kazumi Niinuma,3 Tarou Nakamura,3 Kenichi Matsuura,1 Junichi Yokoyama,1 Kazunori Utsunomiya1 1Division of Diabetes and Endocrinology, Department of Internal Medicine, The Jikei University School of Medicine, Minato-ku, Japan; 2Department of Clinical Research, National Hospital Organization, Utsunomiya National Hospital, Utsunomiya, Japan; 3Research Center, Ajinomoto Pharmaceuticals Co, Ltd, Kanagawa, Japan Abstract: Cilnidipine (Cil), which is an L-/N-type calcium channel blocker (CCB), has been known to provide renal protection by decreasing the activity of the sympathetic nervous system (SNS) and the renin–angiotensin system. In this study, we compared the effects of the combination of Cil and amlodipine (Aml), which is an L-type CCB, with an angiotensin (Ang) II receptor blocker on diabetic cardiorenal damage in spontaneously type 2 diabetic rats. Seventeen-week-old Otsuka Long-Evans Tokushima Fatty rats were randomly assigned to receive Cil, Aml, valsartan (Val), Cil + Val, Aml + Val, or a vehicle (eight rats per group) for 22 weeks. Antihypertensive potencies were nearly equal among the CCB monotherapy groups and the combination therapy groups. The lowering of blood pressure by either treatment did not significantly affect the glycemic variables. However, exacerbations of renal and heart failure were significantly suppressed in rats administered Cil or Val, and additional suppression was observed in those administered Cil + Val. Although Val increased the renin–Ang system, Aml + Val treatment resulted in additional increases in these parameters, while Cil + Val did not show such effects. Furthermore, Cil increased the ratio of Ang-(1–7) to Ang-I, despite the fact that Val and Aml + Val decreased the Ang-(1–7) levels. These actions of Cil + Val might be due to their synergistic inhibitory effect on the activity of the SNS, and on aldosterone secretion through N-type calcium channel antagonism and Ang II receptor type 1 antagonism. Thus, Cil may inhibit the progression of cardiorenal disease in type 2 diabetes patients by acting as an N-type CCB and inhibiting the aldosterone secretion and SNS activation when these drugs were administered in combination with an Ang II receptor blocker. Keywords: calcium channel blocker, combination therapy, angiotensin, type 2 diabetes mellitus" @default.
• W2017776654 created "2016-06-24" @default.
• W2017776654 creator A5002421427 @default.
• W2017776654 creator A5050762792 @default.
• W2017776654 creator A5057522659 @default.
• W2017776654 creator A5060665991 @default.
• W2017776654 creator A5082668876 @default.
• W2017776654 creator A5089785032 @default.
• W2017776654 creator A5090129110 @default.
• W2017776654 date "2014-06-01" @default.
• W2017776654 modified "2023-10-17" @default.
• W2017776654 title "Additive effects of cilnidipine, an L-/N-type calcium channel blocker, and an angiotensin II receptor blocker on reducing cardiorenal damage in Otsuka Long-Evans Tokushima Fatty rats with type 2 diabetes mellitus" @default.
• W2017776654 cites W1497375013 @default.
• W2017776654 cites W163153913 @default.
• W2017776654 cites W1880386821 @default.
• W2017776654 cites W1963930171 @default.
• W2017776654 cites W1969435326 @default.
• W2017776654 cites W197231983 @default.
• W2017776654 cites W1972996565 @default.
• W2017776654 cites W1976034027 @default.
• W2017776654 cites W1980458430 @default.
• W2017776654 cites W1980488800 @default.
• W2017776654 cites W2001722069 @default.
• W2017776654 cites W2002390367 @default.
• W2017776654 cites W2014398586 @default.
• W2017776654 cites W2016442880 @default.
• W2017776654 cites W2021233494 @default.
• W2017776654 cites W2023820004 @default.
• W2017776654 cites W2025722770 @default.
• W2017776654 cites W2026762197 @default.
• W2017776654 cites W2027675986 @default.
• W2017776654 cites W2031753103 @default.
• W2017776654 cites W2036540809 @default.
• W2017776654 cites W2040079480 @default.
• W2017776654 cites W2042847451 @default.
• W2017776654 cites W2047521555 @default.
• W2017776654 cites W2053710318 @default.
• W2017776654 cites W2057539770 @default.
• W2017776654 cites W2059546345 @default.
• W2017776654 cites W2064185517 @default.
• W2017776654 cites W2067853547 @default.
• W2017776654 cites W2069507387 @default.
• W2017776654 cites W2077172957 @default.
• W2017776654 cites W2085864105 @default.
• W2017776654 cites W2086916855 @default.
• W2017776654 cites W2089580948 @default.
• W2017776654 cites W2093962101 @default.
• W2017776654 cites W2098780362 @default.
• W2017776654 cites W2100409734 @default.
• W2017776654 cites W2104285126 @default.
• W2017776654 cites W2114608557 @default.
• W2017776654 cites W2117011543 @default.
• W2017776654 cites W2117060894 @default.
• W2017776654 cites W2130687910 @default.
• W2017776654 cites W2132647859 @default.
• W2017776654 cites W2134479738 @default.
• W2017776654 cites W2135863178 @default.
• W2017776654 cites W2138862624 @default.
• W2017776654 cites W2143978315 @default.
• W2017776654 cites W2149646115 @default.
• W2017776654 cites W2153153065 @default.
• W2017776654 cites W2158020869 @default.
• W2017776654 cites W2159878085 @default.
• W2017776654 cites W2163443918 @default.
• W2017776654 cites W2164834486 @default.
• W2017776654 cites W2165998414 @default.
• W2017776654 cites W2168729080 @default.
• W2017776654 cites W2325897012 @default.
• W2017776654 cites W2326229853 @default.
• W2017776654 cites W2334899541 @default.
• W2017776654 cites W2344626444 @default.
• W2017776654 doi "https://doi.org/10.2147/dddt.s47441" @default.
• W2017776654 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4069052" @default.
• W2017776654 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24970998" @default.
• W2017776654 hasPublicationYear "2014" @default.
• W2017776654 type Work @default.
• W2017776654 sameAs 2017776654 @default.
• W2017776654 citedByCount "5" @default.
• W2017776654 countsByYear W20177766542016 @default.
• W2017776654 countsByYear W20177766542021 @default.
• W2017776654 crossrefType "journal-article" @default.
• W2017776654 hasAuthorship W2017776654A5002421427 @default.
• W2017776654 hasAuthorship W2017776654A5050762792 @default.
• W2017776654 hasAuthorship W2017776654A5057522659 @default.
• W2017776654 hasAuthorship W2017776654A5060665991 @default.
• W2017776654 hasAuthorship W2017776654A5082668876 @default.
• W2017776654 hasAuthorship W2017776654A5089785032 @default.
• W2017776654 hasAuthorship W2017776654A5090129110 @default.
• W2017776654 hasBestOaLocation W20177766541 @default.
• W2017776654 hasConcept C104849204 @default.
• W2017776654 hasConcept C126322002 @default.
• W2017776654 hasConcept C134018914 @default.
• W2017776654 hasConcept C2777180221 @default.
• W2017776654 hasConcept C2777387769 @default.
• W2017776654 hasConcept C2779646130 @default.
• W2017776654 hasConcept C2779716603 @default.
• W2017776654 hasConcept C2780356492 @default.
• W2017776654 hasConcept C2908929049 @default.

• next